Comparison of IV Lignocain and IV Dexmedetomidine for Attenuation of Laryngoscopic Stress Response to Direct Laryngoscopy

NCT07385040 | Completed Phase 2 DMC

• 1 other identifier: ERC-000072/SMBBIT/Aproval/2023
• Study Type: interventional
• Target: 62
• Locations: 1 country
• Sites: 1

Brief Summary

Hemodymanic stress response to direct laryngoscopy and endotracheal intubation is a known phenomenon that occur in almost every patient undergoing general anesthesia before surgical procedure. This response leads to sudden rise in heart rate and blood pressure which may cause serious complications in compromised patients having cardiovascular diseases. There are certain drugs which are used to blunt this response and to prevent the life threatening complications. Intravenous Lignocain is commonly used drug to blunt the laryngoscopic response in our setup. Intravenous Dexmedetomidine is a newer and rarely used drug to prevent stress response to direct laryngoscopy and endotracheal intubation. This study aims to compare the efficacy of both the drugs to provide better control of complications like Arrythmias, stroke and cardiovascular instability.

Conditions

Tachycardia; Hypertension; Mean Arterial Pressure

Keywords

Direct laryngoscopy; Hemodynamic stress response; Lignocaine; Dexmedetomidine

Outcome Measures

Primary Outcomes (1)

• Hemodynamic stress response

  Rise in Heart rate and mean arterial pressure

  1 minute and 3 minute after endotracheal intubation

Study Arms (2)

Group L

ACTIVE COMPARATOR

Group L received IV Lignocain 1.5mg/kg before induction.

Drug: Intravenous Lignocain

Group D

ACTIVE COMPARATOR

Group D received IV Dexmedetomidine infusion 10mics/ kg over 10min before induction

Drug: Intravenous Dexmedetomidine infusion

Interventions

Intravenous Dexmedetomidine infusion DRUG

Dexmedetomidine infusion with dose of 10mics/kg given 10min before induction

Group D

Intravenous Lignocain DRUG

Intravenous ligoncain 1.5mg/kg given 90sec before induction.

Group L

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Patients undergoing general anesthesia for any elective surgery Having ASA 1 or 2 Having mallapatti 1 or 2 Having BMI in between 18-30 kg/m2

You may not qualify if:

• Lack of consent Anticipated difficult airway Pregnancy Sensitivity to either drug

Sponsors & Collaborators

• Shaheed Mohtarma Benazir Bhutto Institue of Trauma: lead

Study Sites (1)

Maryam

Karachi, Sindh, 7523, Pakistan

Location

Related Publications (1)

• Mahiswar AP, Dubey PK, Ranjan A. Comparison between dexmedetomidine and fentanyl bolus in attenuating the stress response to laryngoscopy and tracheal intubation: a randomized double-blind trial. Braz J Anesthesiol. 2022 Jan-Feb;72(1):103-109. doi: 10.1016/j.bjane.2021.02.060. Epub 2021 May 14. PMID: 34000325; PMCID: PMC9373229.

  BACKGROUND

Related Links

• J NTR Univ Health Sci 2015;4:86-90

MeSH Terms

Conditions

Tachycardia; Hypertension

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Cardiac Conduction System Disease; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Vascular Diseases

Study Officials

• Maryam Maryam

  Shaheed Mohtarma Benazir Bhutto Institue of Trauma

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Consultant Anesthesiologist

Model Details: Single blinded, randomised control trial

Study Record Dates

• First Submitted: December 7, 2025
• First Posted: February 3, 2026
• Study Start: April 13, 2023
• Primary Completion: December 31, 2023
• Study Completion: December 31, 2023
• Last Updated: February 3, 2026

Record last verified: 2026-01

Locations

PA (1)